Testing on women “with no recent history of the illness”.  Now what will that prove?  Are they trying to raise the incidence rate among that group so that the vaccine will look better than it otherwise would?  And why is the sample size of the “recurring infections” group so small compared to the "no history" group?  - SM

 

Imunization Newsbriefs

© 2000 Information Inc., Bethesda, MD.

Brought to you by the National Network for Immunization Information (NNii).

Visit NNii’s new website at http://www.immunizationinfo.org.

March 14, 2001

 

“MedImmune Tests Urinary Vaccine”

Washington Post (www.washingtonpost.com) (03/14/01) P. E5; Chea, Terence

 

MedImmune is progressing in its effort to fight urinary tract infections, which affect about 40 percent of U.S. women, by moving into a second set of clinical trials for its vaccine candidate.  Three hundred women with no recent history of the illness will be given three injections of the vaccine over six months to determine the product’s safety and effectiveness.  An early trial of 90 women with recurring infections will be published with the findings of the upcoming trial later this year.

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.